Eli Lilly and Company

Pharmaceuticals
LLY
$ 292 0.28
Share price
$ 277 bn
Market Cap
$ 277 bn
Enterprise Value

Carbon footprint

2.6 Ton
GHG emissions per $ 1 mln investment
0.09x the weighted average for S&P 500
FY2020
How is this calculated?
-9.9%
YOY change in GHG emissions
Weaker than the -11% weighted average for S&P 500
FY2020 vs. previous year

Primary Climate Goal

-10%
Proj. YOY change in GHG emissions (Scope 1 + 2)
Stronger than the -5.1% weighted average for S&P 500
FY2021
How is this calculated?

Eli Lilly and Company aims to achieve net zero for Scope 1 + 2 by 2030


This target has not been verified as science based according to SBTi
Eli Lilly and Company's actual and proj. GHG emissions (Scope 1 + 2) (Kt of CO2e)

GHG emissions and Carbon intensity

Eli Lilly and Company's GHG emissions (location-based) (Kt of CO2e)
Eli Lilly and Company's Carbon intensity (Tons per 1 USDm)

Eli Lilly and Company's carbon footprint

Eli Lilly and Company reported Total CO2e Emissions - Location-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2020 at 710 Kt (-78 /-9.9% y-o-y). Also positively, carbon intensity plunged to 29 t (-6.4 /-18.1% y-o-y).

Eli Lilly and Company's Scope 3 emissions plummeted to 176 Kt (-59 /-25.1% y-o-y). The decline accelerated compared to the CAGR of -12.5% since 4Q'18.

The company is committed to achieving net zero for Scope 1 + 2 by 2030, which translates into the estimated reduction of -71 Kt per annum over the period of FY2021 - FY2030. This target, however, has not been recognised as science-based (and as aligned with Paris Agreement) by the SBTi.

Company environmental metrics

Show more...